Biliary tract cancer

Juan W. Valle(University of Manchester), Robin Katie Kelley(University of California, San Francisco), Bruno Nervi(Pontificia Universidad Católica de Chile), Do‐Youn Oh(Seoul National University Hospital), Andrew X. Zhu(Massachusetts General Hospital)

The Lancet

January 1, 2021

10.1016/s0140-6736(21)00153-7

Cited by 992

Abstract

Related Papers

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung T. Le, Jennifer N. Uram, Hao Wang et al.|New England Journal of Medicine|2015|9.4k

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

Eric Tran, Simon Turcotte, Alena Gros et al.|Science|2014|1.7k

Liver Fluke Induces Cholangiocarcinoma

Banchob Sripa, Sasithorn Kaewkes, Paiboon Sithithaworn et al.|PLoS Medicine|2007|767

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

Daniela Sia, Yujin Hoshida, Augusto Villanueva et al.|Gastroenterology|2013|586

Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis

Randa Tao, Sunil Krishnan, Priya Bhosale et al.|Journal of Clinical Oncology|2015|308